Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $17.18, but opened at $16.19. Mesoblast shares last traded at $16.35, with a volume of 120,019 shares traded.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their target price on shares of Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a research note on Thursday, December 19th. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Finally, Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $13.50.
Get Our Latest Stock Analysis on MESO
Mesoblast Trading Down 2.5 %
The stock's fifty day moving average price is $13.76 and its 200 day moving average price is $9.69. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Mesoblast
Institutional investors have recently modified their holdings of the stock. Signaturefd LLC boosted its holdings in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after purchasing an additional 3,099 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after buying an additional 1,213 shares during the period. Ballentine Partners LLC bought a new position in shares of Mesoblast during the 4th quarter worth $222,000. Perkins Coie Trust Co increased its stake in shares of Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock valued at $94,000 after buying an additional 1,500 shares during the period. Finally, Rathbones Group PLC bought a new stake in shares of Mesoblast in the second quarter valued at about $95,000. 1.43% of the stock is owned by hedge funds and other institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
